This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Multiple myeloma (MM)	MicroRNA-192 (miR-192); miR-194; miR-215; MDM2 p53 binding protein homolog (MDM2; HDM2)	Cell culture and mouse studies suggest that p53-regulated miRNAs could help treat MM. In MM cells, transfection of miR-192, miR-194 or miR-215 decreased cell proliferation and inhibited MDM2 expression compared with transfection of control miRNA. In xenograft mice bearing MM cells, injection of any of these miRNAs lowered cell migration, invasion and tumor growth compared with injection of control miRNA. Next steps include determining if the regulatory status of these miRNAs could be used as a prognostic for MM. At least five companies have inhibitors of MDM2 in preclinical to Phase I testing.	Patent application filed; licensing status unavailable	Picchiori, F. <i>et al. Cancer Cell</i> ; published online Oct. 18, 2010; doi:10.1016/j.ccr.2010.09.005 Contact: Flavia Picchiori, The Ohio State University, Columbus, Ohio e-mail: flavia.picchiori@osumc.edu
<i>SciBX</i> 3(42); doi:10.1038/scibx.2010.1263 Published online Oct. 28, 2010				